FDA grants breakthrough therapy designation to combination for recurrent ovarian cancer

The FDA granted breakthrough therapy designation to VS-6766 with defactinib for treatment of recurrent low-grade serous ovarian cancer, according to the agents’ manufacturer.

The designation applies to use of the combination by women — regardless of KRAS status — who received at least one prior line of therapy, including platinum-based chemotherapy.

Read more from Healio about FDA grants breakthrough therapy designation to combination for recurrent ovarian cancer

Tashatuvango/Shutterstock.com